Cullinan Stock Drop: Timeline Shift, Sector Selling, and Q4 Catalysts
A missed Q3 RA readout, sector pressure, and high short interest hit CGEM. Cash still funds operations into 2029. Next data: November and December.
/ 8 items
#CGEM↓
Cullinan’s CLN-978 Shows Deep B-Cell Depletion and Remissions in Lupus and RA
Cullinan Therapeutics’ CLN-978 T-cell engager showed deep B-cell depletion and clinical remissions in hard-to-treat lupus and rheumatoid arthritis patients after a single dose at EULAR 2026.
Cullinan Therapeutics Receives FDA Orphan Status for Promising AML Therapy CLN-049
FDA gave orphan status to CLN-049 for AML. It uses T cells to attack cancer cells and is in early clinical trials.
UCB Grabs Candid’s BCMA T-Cell Engager – Here’s Why CGEM Investors Are Celebrating
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
Clear Street: Gilead Deal Highlights Huge Potential in Cullinan’s Pipeline
Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.
Cullinan Therapeutics Gets Buy Rating from Citi
Citi gave Cullinan Therapeutics a Buy rating with a $33 target, citing its cancer/autoimmune drug pipeline and key 2026 data readouts as a strong risk/reward opportunity.